Inventor · disambiguated record
Yuchuan Gong
Also filed as: GONG YUCHUAN
20 granted patents·16 pending applications·456 citations·filing 2006–2025
96Inventor score
Top patents by PatentIndex Score
36 records- 0198US9670163B2Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamideVERTEX PHARMA·Filed 2015·Granted Jun 6, 2017·44 cites·8 claims
- 0298US9139530B2Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamideVERTEX PHARMA·Filed 2014·Granted Sep 22, 2015·64 cites·28 claims
- 0398US8754224B2Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamideVERTEX PHARMA·Filed 2013·Granted Jun 17, 2014·97 cites·18 claims
- 0497US10537565B2Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamideVERTEX PHARMA·Filed 2018·Granted Jan 21, 2020·24 cites·26 claims
- 0597US9931334B2Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamideVERTEX PHARMA·Filed 2017·Granted Apr 3, 2018·35 cites·17 claims
- 0696US8410274B2Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamideHURTER PATRICIA·Filed 2012·Granted Apr 2, 2013·109 cites·22 claims
- 0794US8722657B2Salts and crystalline forms of an apoptosis-inducing agentCATRON NATHANIEL·Filed 2011·Granted May 13, 2014·26 cites·3 claims
- 0893US9321765B2Crystalline bromodomain inhibitorsABBVIE INC·Filed 2014·Granted Apr 26, 2016·18 cites·26 claims
- 0992US11291662B2Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamideVERTEX PHARMA·Filed 2019·Granted Apr 5, 2022·5 cites·4 claims
- 1092US8962675B1Atrasentan mandelate saltsABBVIE INC·Filed 2013·Granted Feb 24, 2015·13 cites·11 claims
- 1191US9637476B2Atrasentan mandelate saltsABBVIE INC·Filed 2015·Granted May 2, 2017·8 cites·11 claims
- 1290US2025340550A1Salts and crystalline forms of an apoptosis-inducing agentABBVIE INC·Filed 2024·Application pending·0 cites
- 1384US10730873B2Salts and crystalline forms of an apoptosis-inducing agentABBVIE INC·Filed 2017·Granted Aug 4, 2020·1 cites·9 claims
- 1484US9840502B2Salts and crystalline forms of an apoptosis-inducing agentABBVIE INC·Filed 2015·Granted Dec 12, 2017·2 cites·2 claims
- 1584US9238649B2Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamideABBVIE INC·Filed 2014·Granted Jan 19, 2016·3 cites·2 claims
- 1684US2023263794A1Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamideVERTEX PHARMA·Filed 2022·Application pending·0 cites
- 1784US2023312566A1Salts and crystalline forms of an apoptosis-inducing agentABBVIE INC·Filed 2022·Application pending·0 cites
- 1876US9469673B2Crystaline forms of HCV inhibitorABBVIE INC·Filed 2013·Granted Oct 18, 2016·4 cites·12 claims
- 1974US2020361932A1Salts and crystalline forms of an apoptosis-inducing agentABBVIE INC·Filed 2020·Application pending·0 cites
- 2073US12220417B2Pharmaceutical compositions comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the sameCELGENE CORP·Filed 2022·Granted Feb 11, 2025·0 cites·20 claims
- 2173US2020231593A1Salts and crystalline forms of an apoptosis-inducing agentABBVIE INC·Filed 2020·Application pending·0 cites
- 2273US2020255425A1Salts and crystalline forms of an apoptosis-inducing agentABBVIE INC·Filed 2020·Application pending·0 cites
- 2371US2019194196A1Salts and crystalline forms of an apoptosis-inducing agentABBVIE INC·Filed 2019·Application pending·0 cites
- 2470US8598216B1Ritonavir bis-hydrochlorideACQUASALIENTE MAURIZIO·Filed 2011·Granted Dec 3, 2013·3 cites·18 claims
- 2566US11504378B2Pharmaceutical compositions comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the sameCELGENE CORP·Filed 2020·Granted Nov 22, 2022·0 cites·42 claims
- 2661US2011064811A1Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamideHURTER PATRICIA·Filed 2006·Application pending·0 cites
- 2760US2025255781A1Processes for preparation of 3-d printed pharmaceutical productsBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 2860US2025144108A1Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the sameCELGENE CORP·Filed 2025·Application pending·0 cites
- 2959US2025041271A1Oral suspension of apremilastAMGEN INC·Filed 2021·Application pending·0 cites
- 3055US2025213486A1Solid Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or AdenomyosisABBVIE INC·Filed 2024·Application pending·0 cites
- 3153US2017190692A1Atrasentan mandelate saltsABBVIE INC·Filed 2017·Application pending·0 cites
- 3252US2017066765A1Crystalline bromodomain inhibitorsABBVIE INC·Filed 2016·Application pending·0 cites
- 3350US2016237085A1Crystalline bromodomain inhibitorsABBVIE INC·Filed 2016·Application pending·0 cites
- 3449US2015175612A1Crystal formsABBVIE INC·Filed 2014·Application pending·0 cites
- 3547US9174944B1Crystalline lopinavir/surfactant adductsGONG YUCHUAN·Filed 2011·Granted Nov 3, 2015·0 cites·9 claims
- 3642US12083227B2Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosisABBVIE INC·Filed 2018·Granted Sep 10, 2024·0 cites·46 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →